A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.

Masarova L, Reeves BN, El Chaer F, Foltz L, Tashi T, Abu-Zeinah G, Lucas J, Halpern AB, Maze D, Qin A, Safah H, Lan F, O'Connell CL, Goel S, Rein L, Fang B, How J, Babu S, Li Z, Cerquozzi S, Oh ST, Hunter AM, Podoltsev N, Vachhani P, Yacoub A, Cunningham JM, Hillis C, Otoukesh S, Zagrijtschuk O, Castro H, Bose P

Open source

DOI: 10.3389/fmed.2025.1548590
Published: 2025
Container: Frontiers in medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fmed.2025.1548590,
  title = {A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.},
  author = {Masarova L and Reeves BN and El Chaer F and Foltz L and Tashi T and Abu-Zeinah G and Lucas J and Halpern AB and Maze D and Qin A and Safah H and Lan F and O'Connell CL and Goel S and Rein L and Fang B and How J and Babu S and Li Z and Cerquozzi S and Oh ST and Hunter AM and Podoltsev N and Vachhani P and Yacoub A and Cunningham JM and Hillis C and Otoukesh S and Zagrijtschuk O and Castro H and Bose P},
  year = {2025},
  journal = {Frontiers in medicine},
  doi = {10.3389/fmed.2025.1548590},
  url = {https://doi.org/10.3389/fmed.2025.1548590}
}

RIS

TY  - JOUR
TI  - A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.
AU  - Masarova L
AU  - Reeves BN
AU  - El Chaer F
AU  - Foltz L
AU  - Tashi T
AU  - Abu-Zeinah G
AU  - Lucas J
AU  - Halpern AB
AU  - Maze D
AU  - Qin A
AU  - Safah H
AU  - Lan F
AU  - O'Connell CL
AU  - Goel S
AU  - Rein L
AU  - Fang B
AU  - How J
AU  - Babu S
AU  - Li Z
AU  - Cerquozzi S
AU  - Oh ST
AU  - Hunter AM
AU  - Podoltsev N
AU  - Vachhani P
AU  - Yacoub A
AU  - Cunningham JM
AU  - Hillis C
AU  - Otoukesh S
AU  - Zagrijtschuk O
AU  - Castro H
AU  - Bose P
PY  - 2025
JO  - Frontiers in medicine
DO  - 10.3389/fmed.2025.1548590
UR  - https://doi.org/10.3389/fmed.2025.1548590
ER  -

APA

L, M., BN, R., F, E. C., L, F., T, T., G, A., J, L., AB, H., D, M., A, Q., H, S., F, L., CL, O., S, G., L, R., B, F., J, H., S, B., Z, L., S, C., ST, O., AM, H., N, P., P, V., A, Y., JM, C., C, H., S, O., O, Z., H, C., & P, B. (2025). A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.. Frontiers in medicine. https://doi.org/10.3389/fmed.2025.1548590

Source records

pubmed · retrieved 2026-09-26T18:21:24.508Z